Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure

  • Mora-Ayestarán, Nerea|||0000-0002-2127-5287
  • Ochoa, Juan Pablo|||0000-0002-7966-0313
  • Gómez-González, Cristina
  • Navarro-Peñalver, Marina
  • Gallego-Delgado, María|||0000-0003-0726-9646
  • Larrañaga-Moreira, José M.|||0000-0002-8370-5158
  • Robles-Mezcua, Ainhoa
  • Basurte-Elorz, María Teresa|||0000-0002-8689-0301
  • Rodriguez-Palomares, Jose Fernando
  • Climent-Paya, Vicente
  • Jiménez-Jaímez, Juan
  • Mogollón-Jiménez, Maria Victoria
  • García-Granja, Pablo Elpidio|||0000-0002-0750-1567
  • García-Álvarez, Ana|||0000-0002-1718-2424
  • Peña-Peña, María Luisa
  • Alvarez Barredo, María|||0000-0002-8545-8138
  • Ripoll-Vera, Tomás|||0000-0001-9222-325X
  • Palomino-Doza, Julián
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Tirón, Coloma
  • Fernández, Ana Isabel|||0000-0002-1509-5191
  • Sabater-Molina, María
  • Toranzo, Inés
  • Crespo-Leiro, Maria Generosa|||0000-0002-3085-167X
  • Doncel-Abad, Victoria
  • Lacuey-Lecumberri, Gemma
  • Limeres-Freire, Javier
  • García-Álvarez, Maria I
  • Cabrera-Borrego, Eva|||0000-0003-2997-2391
  • Kounka-Ait El Maalem, Zineb
  • Vilches, Silvia
  • González-López, Esther
  • Villacorta, Eduardo|||0000-0003-0486-1740
  • García Pinilla, José Manuel|||0000-0001-5999-5741
  • Barriales-Villa, Roberto|||0000-0002-6721-3487
  • Gimeno-Blanes, Juan Ramón
  • García-Pavía, Pablo|||0000-0002-5470-2257
  • Domınguez, Fernando|||0000-0001-8408-363X
Certain genetic forms of dilated cardiomyopathy (DCM) entail a higher arrhythmic risk. It is unknown whether DCM patients with high-risk arrhythmic genotypes also develop more advanced heart failure (AHF) complications. AHF events were studied according to DCM genotype. Clinical data from 1203 genotyped DCM patients were collected from 19 Spanish centres. Patients were classified into high-risk arrhythmic genotypes (LMNA, FLNC, desmosomal genes, PLN, TMEM43, RBM20), TTN, other genes, and genotype negative (Gen-). The primary endpoint was a composite of AHF events (ventricular assist device implantation, heart transplant, and AHF-related mortality). The secondary endpoint was a combination of malignant ventricular arrhythmias (MVA). A DCM-causing variant was identified in a high-risk arrhythmic gene in 185 patients (15.4%), 193 (16.0%) had variants in TTN, 134 (11.1%) in other genes, and 691 (57.4%) were Gen-. After a median follow-up of 5.7 years (interquartile range 2.9-9.1 years), AHF events occurred in 45 (24.3%) patients in the high-risk arrhythmic group, while in 25 (18.7%), 25 (13.0%), and 70 (10.1%) patients with other genotypes, TTN, and Gen-, respectively (hazard ratio 1.85, 95% confidence interval 1.31-2.61 for high-risk arrhythmic genes compared with other groups). MVA occurred in 55 patients (29.7%) (hazard ratio 2.52, 95% confidence interval 1.81-3.51 for high-risk genotypes vs other groups). High-risk arrhythmic genotype was the main independent predictor of AHF in multivariate analysis. High-risk arrhythmic genotype and late gadolinium enhancement were independent predictors of MVA. Patients with high-risk arrhythmic genotypes also experience more AHF events, supporting a differential therapeutic approach in this group of patients beyond sudden death prevention.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Overexpression of wild-type TMEM43 improves cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5

  • Lalaguna, Laura
  • Arévalo-Núñez De Arenas, María
  • López-Olañeta, Marina
  • Villalba-Orero, María
  • Jiménez-Riobóo, Rafael J.
  • Gómez-Gaviro, María Victoria
  • Isern, Joan
  • Muñoz Cánoves, Pura, 1962-
  • Byrne, Barry J.
  • Ochoa, Juan Pablo
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is the most aggressive type of ARVC, caused by a fully penetrant missense mutation (p.S358L) in TMEM43 (transmembrane protein 43). Pathologically, the disease is characterized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results in heart failure and sudden cardiac death. Current therapeutic options are limited, and no specific therapies targeting the primary cause of the disease have been proposed. METHODS: We investigated whether overexpression of wild-type (WT) TMEM43 could overcome the detrimental effects of the mutant form. We used transgenic mouse models overexpressing either WT or mutant (S358L) TMEM43 to generate a double transgenic mouse line overexpressing both forms of the protein. In addition, we explored if systemic delivery of a codon-optimized self-complementary adeno-associated virus bearing WT-TMEM43 could improve disease progression assessed by ECG and echocardiography. RESULTS: Double transgenic mice overexpressing both WT and mutant TMEM43 forms showed delayed ARVC5 onset, improved cardiac contraction, and reduced ECG abnormalities compared with mice expressing S358L-TMEM43. In addition, cardiomyocyte death and myocardial fibrosis were reduced, with an overall increase in survival. Finally, we demonstrated that a single systemic administration of an adeno-associated virus carrying codon-optimized WT-TMEM43 prevents ventricular dysfunction and ECG abnormalities induced by S358L-TMEM43. CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease., This study was funded by the Pathfinder Cardiogenomics program of the European Innovation Council of the European Union (DCM-NEXT project; project number: 101115416) and grants PID2021-124629OB-I00, TED2021-129774BC22, and PLEC2022-009235 funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033), the European Union's NextGenerationEU/PRTR (Plan de Recuperación, Transformación y Resiliencia de España), and Fondo Europeo de Desarrollo Regional (FEDER) to E. Lara-Pezzi. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Overexpression of wild-type TMEM43 improves cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5

  • Lalaguna, Laura
  • Arévalo-Núñez De Arenas, María
  • López-Olañeta, Marina
  • Villalba-Orero, María
  • Jiménez-Riobóo, Rafael J.
  • Gómez-Gaviro, María Victoria
  • Isern, Joan
  • Muñoz Cánoves, Pura, 1962-
  • Byrne, Barry J.
  • Ochoa, Juan Pablo
  • García-Pavía, Pablo
  • Lara-Pezzi, Enrique
BACKGROUND: Arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5) is the most aggressive type of ARVC, caused by a fully penetrant missense mutation (p.S358L) in TMEM43 (transmembrane protein 43). Pathologically, the disease is characterized by dilation of the cardiac chambers and fibrofatty replacement of the myocardium, which results in heart failure and sudden cardiac death. Current therapeutic options are limited, and no specific therapies targeting the primary cause of the disease have been proposed. METHODS: We investigated whether overexpression of wild-type (WT) TMEM43 could overcome the detrimental effects of the mutant form. We used transgenic mouse models overexpressing either WT or mutant (S358L) TMEM43 to generate a double transgenic mouse line overexpressing both forms of the protein. In addition, we explored if systemic delivery of a codon-optimized self-complementary adeno-associated virus bearing WT-TMEM43 could improve disease progression assessed by ECG and echocardiography. RESULTS: Double transgenic mice overexpressing both WT and mutant TMEM43 forms showed delayed ARVC5 onset, improved cardiac contraction, and reduced ECG abnormalities compared with mice expressing S358L-TMEM43. In addition, cardiomyocyte death and myocardial fibrosis were reduced, with an overall increase in survival. Finally, we demonstrated that a single systemic administration of an adeno-associated virus carrying codon-optimized WT-TMEM43 prevents ventricular dysfunction and ECG abnormalities induced by S358L-TMEM43. CONCLUSIONS: Overexpression of WT-TMEM43 improves the pathological phenotype in a mouse model of ARVC5. Adeno-associated virus-mediated delivery of WT-TMEM43 offers a promising and specific therapy for patients suffering from this highly lethal disease., This study was funded by the Pathfinder Cardiogenomics program of the European Innovation Council of the European Union (DCM-NEXT project; project number: 101115416) and grants PID2021-124629OB-I00, TED2021-129774BC22, and PLEC2022-009235 funded by the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033), the European Union's NextGenerationEU/PRTR (Plan de Recuperación, Transformación y Resiliencia de España), and Fondo Europeo de Desarrollo Regional (FEDER) to E. Lara-Pezzi. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033).